




DIGITAL DRUG DELIVERY AND THE FUTURE OF PHARMA

88%



Almost all report that digital drug delivery is "Extremely" or "Very" important to future plans

90%




But smaller companies think it's even more important

1/3

OF PHARMA IS ALREADY IN THE MARKET WITH DIGITAL DRUG DELIVERY

34%



A TYPICAL COMPANY WILL BE IN MARKET WITHIN 2 YEARS



BUT WILL TAKE 6-10 YEARS TO BE MOSTLY DIGITIZED

92%

EXPECT BETTER PATIENT OUTCOMES FROM DIGITAL DRUG DELIVERY



And Pharma will feel healthier too

60% REDUCED COSTS

54% IMPROVED EFFICIENCY

53% MORE PATIENT SUPPORT

50% DATA-DRIVEN R&D



THERAPEUTIC AREAS WITH THE GREATEST POTENTIAL

57% RESPIRATORY

RESPIRATORY

64% ENDOCRINE

ENDOCRINE

38% INFECTIOUS DISEASES


INFECTIOUS DISEASES

43% CARDIO-VASCULAR

CARDIO-VASCULAR


52% INFLAMMATORY /IMMUNE

INFLAMMATORY /IMMUNE



89%

BELIEVE DIGITAL DRUG DELIVERY REQUIRES ORGANIZATIONAL CHANGES



CHALLENGES


Data privacy risk 40%

Device/connect costs too high 39%

Patient internet connectivity issues 39%

Regulatory concerns 39%

99% WILL NEED EXTERNAL EXPERTISE



We are on the cusp of a revolution in digital drug delivery. Find out how Molex can help your company accelerate its own digital transformation.

[DOWNLOAD FULL SURVEY DATA HERE](#)

